ARQT יחס מהיר Arcutis Biotherapeutics

The commercialization of the innovative ZORYVE cream sets the trajectory of the dynamics that the GURU.Markets system reflects on this chart by tracking rapid liquidity for Arcutis Biotherapeutics (ARQT). The model is based on outsourcing production via CMOs, while high development costs and patents create a defensive barrier. The value of 2.72 reflects the baseline level of the metric assessing the company's ability to cover short-term debts excluding inventory.

For Arcutis Biotherapeutics (ARQT), which is protected by FDA patents in dermatology, the quick ratio serves as an indicator of the ability to cover short-term debts without liquidating inventory. This calculation compares only cash and accounts receivable against liabilities, allowing the investor to assess the real financial stability of the business amid high costs for clinical trials and drug promotion.